Stay updated on Cabometyx + Avelumab in mRCC Clinical Trial

Sign up to get notified when there's something new on the Cabometyx + Avelumab in mRCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabometyx + Avelumab in mRCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:41:07.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to an open-label, non-controlled, non-randomized phase I dose-finding study of Cabometyx + Avelumab in patients with metastatic renal cell carcinoma (mRCC). The change may reflect an adjustment in the safety, feasibility, or recommended phase 2 dose of the treatment combination.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:03.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    42%
    Check dated 2024-05-22T20:56:31.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:24:43.000Z thumbnail image

Stay in the know with updates to Cabometyx + Avelumab in mRCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabometyx + Avelumab in mRCC Clinical Trial page.